Globus Medical Reports Second Quarter 2020 Results

Go back to Globus Medical Reports Second Quarter 2020 Results

Northland Capital Markets Upgrades Globus Medical (GMED) to Outperform

August 6, 2020 7:48 AM EDT

Northland Capital Markets analyst Jason Wittes upgraded Globus Medical (NYSE: GMED) from Market Perform to Outperform with a price target of $65.00.

The analyst commented, "2Q revs of $148.9mm (-23.4%) and EPS of $0.07, easily bested consensus of $99.7mm and ($0.11). Not a complete surprise,... More

Globus Medical (GMED) Tops Q2 EPS by 18c

August 5, 2020 5:13 PM EDT

Globus Medical (NYSE: GMED) reported Q2 EPS of $0.07, $0.18 better than the analyst estimate of ($0.11). Revenue for the quarter came in at $148.9 million versus the consensus estimate of $99.73 million.

The Globus Team performed extremely well in the second quarter, said Dave Demski, President and CEO. Our worldwide revenue was down 23% in the quarter, an exceptional result when compared to our... More